603392:SSEBeijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A Analysis
Data as of 2026-08-25 - not real-time
CN¥27.89
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. trades at ¥27.89, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it lost 1.8%. Relative strength is 41.5 — neutral — and the MACD signal is bearish. Recent trading has carved out support near ¥27.41 and resistance around ¥32.55.
Valuation screens as overvalued: a P/E of 48.9 sits above the sector average of 31.1. The average analyst target implies 16.2% above today's level. Revenue is growing at 18.6% on a -18.9% profit margin.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 50.7%, a beta of 0.26 and a maximum drawdown of 57.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 5 out of 10.
Valuation screens as overvalued: a P/E of 48.9 sits above the sector average of 31.1. The average analyst target implies 16.2% above today's level. Revenue is growing at 18.6% on a -18.9% profit margin.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 50.7%, a beta of 0.26 and a maximum drawdown of 57.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 5 out of 10.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 5/10
Key Factors
- Trading below the 200-day average of 39.44
- MACD momentum is negative
- 30-day volatility of 50.7%
Medium Term
1–3 yearsCautious
Model confidence: 5/10
Key Factors
- P/E of 48.9 versus sector average of 31.1
- Trading below the 200-day average of 39.44
- Analyst targets imply +16.2% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- P/E of 48.9 versus sector average of 31.1
- Negative profit margin of -18.9%
- Analyst targets imply +16.2% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth18.60%
Profit Margin-18.90%
P/E Ratio48.9
ROE-3.31%
ROA-3.11%
Debt/Equity2.72
P/B Ratio3.0
Op. Cash FlowCN¥75.0M
Free Cash FlowCN¥-302207584
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI41.5
SupportCN¥27.41
ResistanceCN¥32.55
MA 20CN¥29.91
MA 50CN¥29.02
MA 200CN¥39.44
MACDBearish
VolumeIncreasing
Fear & Greed Index93.13
Valuation
Fair ValueCN¥4.27
Target PriceCN¥32.40
Upside/Downside16.17%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.26
Volatility50.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.